4-(4-fluorophenoxy)-1-butyn-3-one | 524714-02-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(4-fluorophenoxy)-1-butyn-3-one
• 英文别名: 1-(4-fluorophenoxy)but-3-yn-2-one
• CAS: 524714-02-1
• 化学式: C₁₀H₇FO₂
• 分子量: 178.163
• InChiKey: ARUJVOKREAIMBP-UHFFFAOYSA-N

物化性质

• 沸点：
  299.6±20.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-fluorophenoxy)-1-butyn-3-one 在 B-isopinocampheyl-9-borabicyclo[3.3.1]nonane 作用下， 以 四氢呋喃 为溶剂， 生成 (3R)-4-(4-fluorophenoxy)-3-hydroxy-1-butyne 、 (3S)-4-(4-fluorophenoxy)-3-hydroxy-1-butyne
  参考文献：
  名称：

  Novel 3-Oxa Lipoxin A₄ Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo

  摘要：

  Lipoxin A(4) (LXA(4)) is a structurally and functionally distinct natural product called an eicosanoid, which displays immunomodulatory and anti-inflammatory activity but is rapidly metabolized to inactive catabolites in vivo. A previously described analogue of LXA(4), methyl (5R,6R,7E,9E,11Z,13E,15S)-16-(4-fluorophenoxy)-5,6,15-trihydroxy-7,9,11,13-hexadecatetraenoate (2, ATLa), was shown to have a poor pharmacokinetic profile after both oral and intravenous administration, as well as sensitivity to acid and light. The chemical stability of the corresponding E,E,E-trien-11-yne analogue, 3, was improved over 2 without loss of efficacy in the mouse air pouch model of inflammation. Careful analysis of the plasma samples from the pharmacokinetic assays for both 2 and 3 identified a previously undetected metabolite, which is consistent with metabolism by beta-oxidation. The formation of the oxidative metabolites was eliminated with the corresponding 3-oxatetraene, 4, and the 3-oxatrien-11-yne, 5, analogues of 2. Evaluation of 3-oxa analogues 4 and 5 in calcium ionophore-induced acute skin inflammation model demonstrated similar topical potency and efficacy compared to 2. The 3-oxatrien-11-yne analogue, 5, is equipotent to 2 in an animal model of inflammation but has enhanced metabolic and chemical stability and a greatly improved pharmacokinetic profile.

  DOI：

  10.1021/jm030569l
• 作为产物：
  描述：

  4-氟苯氧乙酸 在 草酰氯 、 potassium carbonate 、 乙酸乙酯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 22.5h， 生成 4-(4-fluorophenoxy)-1-butyn-3-one
  参考文献：
  名称：

  Novel 3-Oxa Lipoxin A₄ Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo

  摘要：

  Lipoxin A(4) (LXA(4)) is a structurally and functionally distinct natural product called an eicosanoid, which displays immunomodulatory and anti-inflammatory activity but is rapidly metabolized to inactive catabolites in vivo. A previously described analogue of LXA(4), methyl (5R,6R,7E,9E,11Z,13E,15S)-16-(4-fluorophenoxy)-5,6,15-trihydroxy-7,9,11,13-hexadecatetraenoate (2, ATLa), was shown to have a poor pharmacokinetic profile after both oral and intravenous administration, as well as sensitivity to acid and light. The chemical stability of the corresponding E,E,E-trien-11-yne analogue, 3, was improved over 2 without loss of efficacy in the mouse air pouch model of inflammation. Careful analysis of the plasma samples from the pharmacokinetic assays for both 2 and 3 identified a previously undetected metabolite, which is consistent with metabolism by beta-oxidation. The formation of the oxidative metabolites was eliminated with the corresponding 3-oxatetraene, 4, and the 3-oxatrien-11-yne, 5, analogues of 2. Evaluation of 3-oxa analogues 4 and 5 in calcium ionophore-induced acute skin inflammation model demonstrated similar topical potency and efficacy compared to 2. The 3-oxatrien-11-yne analogue, 5, is equipotent to 2 in an animal model of inflammation but has enhanced metabolic and chemical stability and a greatly improved pharmacokinetic profile.

  DOI：

  10.1021/jm030569l

文献信息

• Lipoxin A4 analogs
  申请人：Schering Aktiengesellschaft

  公开号：US20040162433A1

  公开（公告）日：2004-08-19

  This invention is directed to lipoxin A 4 analogs of the following formula (I) and (II): 1 wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

  本发明涉及以下公式（I）和（II）的脂氧素A4类似物：1其中R1，R2，R3，R4和R5如本文所述。这些类似物在治疗人类的炎症和自身免疫性疾病方面非常有用。这些类似物还在治疗人类的肺部或呼吸道炎症方面非常有用。
• Intermediates for the preparation of lipoxin A4 analogs
  申请人：Grossbach Danja

  公开号：US20070105949A1

  公开（公告）日：2007-05-10

  This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A 4 analogs of the following formulas (I) and (II): wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

  本发明涉及化合物，其作为合成脂氧素A4类似物的中间体有用，该类似物的化学式为(I)和(II)，其中R1、R2、R3、R4和R5如本文所述。这些类似物对于治疗人体内的炎症和自身免疫性疾病有用。这些类似物也对于治疗人体内的肺部或呼吸道炎症有用。
• LIPOXIN A4 ANALOGS
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP1472209A2

  公开（公告）日：2004-11-03
• US6831186B2
  申请人：——

  公开号：US6831186B2

  公开（公告）日：2004-12-14
• US7223798B2
  申请人：——

  公开号：US7223798B2

  公开（公告）日：2007-05-29